Financial Trading Blog
Stock of the day 05/08/2015 – GW Pharmaceuticals PLC
The company announces its third quarter results on Thursday.
After opening the year at £3.69 GW Pharmaceuticals has only now just begin to see any kind of sustained decline. Near 20% jumps in the middle of March and April did most of the grunt work in lifting the stock, whilst more gradual gains across May and June took GW to an all-time high of £7.08 by the year’s half way point. Since then, however, the stock hasn’t been able to maintain this growth, and spent the second half of July in the red. GW Pharmaceuticals has a current trading price of £5.99 (IT-Finance.com, 05/08/2015).
(Source: IT-Finance.com 05/08/2015)
Similarly its US stock listing has risen from $68.31 at the start of 2015 to high of $133.87 at the end of June; it has a current trading price of $112.60 (IT-Finance.com, 05/08/2015).
(Source: IT-Finance.com 05/08/2015)
The company’s half year results back in May had a few issues; revenue slipped to £14.3 million from £15 million largely due to increased R&D expenditure, from £21 million to £30.5 million. Overall this led GW Pharmaceuticals to post a widening pre-tax loss, from £10.6 million to £13.7 million year-on-year. However, these financial issues were swallowed by investors with little disruption to GW’s ascendance because of the increasing strength of its drugs pipeline.
The main star of that second quarter reports was Epidiolex. The company announced that the cannabis-based product was about to enter phase 3 trials for its treatment of Dravet syndrome and Lennox-Gastaut syndrome, as well as the fact it had been awarded a Notice of Allowance issued by the US Patent and Trademark Office.
In terms of its upcoming third quarter announcement, analysts are expecting a widening of losses, from $0.66 to $1.16 per share, alongside a slip in revenue, from $13.02 million to $12.86 million. However, these headline figures are likely not to matter as much to investors as the company’s pipeline updates, especially comments on Epidolex’s phase 3 trials. Also important will be the progress of tests to see whether its multiple sclerosis drug Sativex (the first natural cannabis plant derivate to gain full market approval ever) can be used to treat pain associated with cancer, something it ran into problems with back in January.
GW Pharmaceuticals has a consensus rating of ‘Buy’ with an average target price of $137.59 (for its US listing).
It's easy to open an account
- Fill in our simple online application form
- Fund your account
- Start trading the global markets instantly!
SEARCH FOR AN ARTICLE:
Enter a keyword and search for all relevant articlesMARKET ANALYSIS
RECENT POSTS
DISCLAIMER
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 64% of retail investors lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money. For professional clients, spread betting and CFD trading can also result in losses larger than your initial stake or deposit.
Spreadex Ltd is authorised and regulated by the Financial Conduct Authority, provides an execution only service and does not provide advice in any way. Nothing within this update should be deemed to constitute the provision of investment advice, recommendations, any other professional advice in any way, or a record of our trading prices. This update does not constitute or form part of an offer of, or solicitation for a transaction in any financial instrument, nor shall it or the fact of its distribution form the basis of, or be relied on in connection with, any contract therefore. Any persons placing trades based on their interpretation of the comments or information within this update does so entirely at their own risk.
No representation, warranty, or undertaking, express or limited, is given as to the accuracy or completeness of the information or opinions contained within this update by Spreadex Ltd or any of its employees and no liability is accepted by such persons for the accuracy or completeness of any such information or opinions. As such, no reliance may be placed for any purpose on the information and opinions contained within this update.
The information contained within this update is the intellectual property of Spreadex Ltd and is protected by UK and International copyright laws. All rights reserved. Users may however freely download, distribute and reproduce extracts of the contents, subject always to accrediting Spreadex Ltd as the source and providing a hyperlink to www.spreadex.com.
